Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03608579 · ClinicalTrials.gov registry record · Phase 1

Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA

A Phase 1 study of Osteoarthritis, Hip, sponsored by Mayo Clinic.

Active
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT03608579 is a Phase 1 study of Osteoarthritis, Hip that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 1,272-participant average among 20 other Osteoarthritis, Hip trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03608579, a Phase 1 study of Osteoarthritis, Hip, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Will injection(s) of autologous culture-expanded AMSCs be safe and efficacious for treatment of painful Hip OA, and if so, which dosing regimen is most effective?

Conditions Studied

Interventions

  • DRUG Autologous Adipose Derived Mesenchymal Stromal Cells

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2018-11-05
Est. Completion 2026-12
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT03608579

The ClinicalTrials.gov registry entry for NCT03608579 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,272-participant average among 20 other Osteoarthritis, Hip trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis, Hip appearing as the primary indexed condition, and to 1 intervention - of which Autologous Adipose Derived Mesenchymal Stromal Cells is the first listed.

NCT03608579 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT03608579 about?

NCT03608579 is a clinical study titled "Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA". Will injection(s) of autologous culture-expanded AMSCs be safe and efficacious for treatment of painful Hip OA, and if so, which dosing regimen is most effective?

What is the current status of trial NCT03608579?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-11-05. Estimated completion is 2026-12.

What conditions does trial NCT03608579 study?

This clinical trial studies the following conditions: Osteoarthritis, Hip.

What interventions are being tested in trial NCT03608579?

The interventions under investigation include: Autologous Adipose Derived Mesenchymal Stromal Cells (DRUG).

Who is sponsoring clinical trial NCT03608579?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03608579 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis, Hip

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.